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1.1 Oral diseases 
The oral cavity is the first section of the digestive system and consists of different anatomical 
structures, including teeth, gingiva and their supportive tissues, hard and soft palate, tongue, 
lips and a mucosal membrane lining the inner surface of the cheek. Currently oral diseases 
are considered as a serious threat to public health that challenges health systems around the 
world. They may possibly directly affect a limited locale of the human body, but their 
outcomes and impacts have an effect on the body as a whole (FDI World Dental Federation, 
2015). Apart from trauma from injuries, there are many immune-mediated inflammatory 
mucocutaneous diseases that have an effect on the oral cavity, most of them presenting 
clinically with varied degrees of blistering, sloughing, erosions, ulcerations and pain 
(Perschbacher, 2018). But the most common acquired oral diseases worldwide are tooth 
decay and periodontal diseases. 
 
1.2 Periodontitis  
1.2.1 Aetiology and risk factors 
Periodontal disease is one of the world’s most prevalent chronic diseases, which is 
characterized by various degenerative and inflammatory states of gums, periodontal 
ligaments, alveolar bone and dental cementum (Jain et al., 2008). It is common in all groups, 
ethnicities, races, both genders and is mainly categorized into chronic periodontitis and 
aggressive periodontitis. Chronic periodontitis results from repeated attack from complex 
microbiota, whereas aggressive periodontitis involves rapid attachment loss and bone 
destruction, the destruction being non proportional to the microbial load. Further 
characterization depends on the magnitude of bone loss (localized or generalized) and the 
severity of the disease (slight, moderate or advanced). 
The microbial growth of the pathogens, which occurs due to the accumulation of subgingival 
plaque is said to be the main cause of this disease (Zilberman and Elsner, 2008).The 
periodontal structures which support the gums and teeth are primarily damaged by harmful 
by-products and enzymes from periodontal bacteria, like leucotoxins, collagenases, 
fibrinolysins and other proteases (Pihlstrom et al., 2005), along with the triggered host 
immune response (Pihlstrom et al., 2005). The early stage of the disease the inflammation is 
limited to the gingiva and this condition is named as gingivitis and it can be reversed by 
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regularly maintaining good oral hygiene (Pihlstrom et al., 2005). However, if the plaque is 
not removed, it hardens to form tartar or calculus, which cannot be removable by daily 
brushing and flossing. Subsequently, the bacteria start invading deeper tissues, and the 
collagen and periodontal ligaments that support the teeth in place are degenerated (Singh et 
al., 2012b), inducing also resorption of the alveolar bone. Thus, a space is generated between 
the gingiva and the tooth due to the migration of gingival epithelium along the tooth surface 
known as “periodontal pocket” and the disease condition stemming from this is known as 
“periodontitis”. This periodontal pocket serves microflora to reside effortlessly, thus 
contribute to worsening of the condition. If this condition is not treated, the tooth loosens and 
finally gets dislodged, causing edentulism.  
According to WHO, 10–15 % of the worldwide population possesses severe periodontitis 
(Jacob, 2012), therefore the comprehension of the mechanisms leading to it is actively 
pursued. A microbiological cause is evident, but a massive count of microorganisms is 
normally present in the buccal cavity, as most of them live harmlessly in symbiosis with the 
healthy host (Ismail et al., 2013; Pihlstrom et al., 2005; Singh et al., 2012a). Evidence has 
been gathered showing that there is a shift in the type of microorganisms populating the oral 
cavity, from Gram-positive aerobic species in healthy individuals to Gram-negative anaerobic 
species in periodontitis patients (Ismail et al., 2013).  
Actually, the organisms mainly responsible for periodontitis are Gram-negative anaerobic 
microflora like Bacteroides spp. (B. intermedius and B. gingivalis), fusiform organisms 
(Aggregatibacter actinomycetemcomitans, Wolinella recta, Eikenella spp., Porphyromonas 
gingivalis, Tannerella forsythensis), various bacilli and cocci and spirochetes. In addition to 




                         
Figure 1. Aetiology and pathogenisis of periodontitis (Gross et al., 2017). 
 
The inflammatory response in this disease condition involves activation of T lymphocytes, 
neutrophils, release of antibodies, chemical inflammatory mediators (cytokines, chemokines 
and C-reactive protein), and lipopolysaccharides present in the Gram-negative bacterial cell 
walls (Singh et al., 2015). Whereas, fibroblasts are stimulated by IL-1 and matrix 
metalloproteinases (MMPs) are secreted by neutrophil granulocytes, resulting in enhanced 
collagen degeneration, activation of cytokines and chemokines. Also osteoclast activity is 
augmented, due to TNF-α, by suppressing the production of collagen. Osteoclasts are 
activated by the release of antibodies and secretion of receptor activator of nuclear factor 
kappa-B (RANK) ligands by the lymphocytes (Parnami et al., 2013).  
Furthermore, several researchers have proposed possible connections of periodontitis with 
common systemic diseases. The infection intiated by this disease causes bacteraemia, 
endotoxaemia and promotes systemic inflammatory response which play major role in 
systemic diseases. Diabetes mellitus (Lalla & Papapanou, 2011; Santos et al., 2012), 
psychological stress (Kaur et al., 2014b), genetic susceptibility (Kaur et al., 2016), host 
immune response, osteoporosis (Esfahanian et al., 2012; Guiglia et al., 2013) and ageing are 
the various well-established risk factors to periodontal disease (Van Dyke and Dave, 2005). 
Associations with respiratory (Saini et al., 2010), low birth weights and cardiovascular 





1.2.2 Diagnosis and treatment 
Clinical examination utilizing periodontal probe (Fig. 2) in combination with X-ray imaging 
are used to diagnose deeper pockets, and subsequently, microbiological techniques are done 
for the precise analysis of causative agents (Nair and Anoop, 2012). A reasonably accurate 
estimate of sulcus or pocket depth have been recorded with probe measurements. It is now 
obvious that probing depth measured from the gingival margin not often corresponds to 
sulcus or pocket depth. The difference is least in the absence of inflammatory changes and 
increases with increasing degrees of inflammation. In the presence of this disease condition 
the probe tip go by the inflamed tissues to stop at the level of the most intact coronal dento-
gingival fibers, in the section of 0.3-0.5 mm above the apical termination of the junctional 
epithelium. Following periodontal therapy, decreased probing depth measurements may be 
due in part to reduced penetrability of the gingival tissues by the probe. Above all the 
interpretation of periodontal probing in the dental practice may need reassessment in relation 
to periodontal probing measurements to actual sulcus or pocket depth, (Listgarten, 1980). 
                   
Figure 2. Clinical examination by a periodontal probe (Gross et al., 2017). 
 
Depending on the severity of the disease a variety of surgical and nonsurgical treatments can 
be made available. Nevertheless, scaling and root planning is considered as the gold standard 
nonsurgical treatment given in periodontitis (Tariq et al., 2012): in this technique, the dentist 
uses various instruments to mechanically remove subgingival biofilm and calculus (Sanz et 
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al., 2012). These events have some drawbacks, like inability to reach the deep pockets and 
furcations (Herrera et al., 2012). Hence, antimicrobial drugs are administered as adjunct to 
these treatments for complete cure of the ailment, predominantly the aggressive periodontitis 
(Ahuja et al., 2012; Arweiler et al., 2014), but the infection caused by the bacterial aetiology 
should be considered for selecting the appropriate antibiotic and concurrently maintenance of 
daily oral hygiene by the patient is mandatory (Schwach-Abdellaoui et al., 2000).  
The possible outcome of therapeutic success or failure is not only achieved by the 
antimicrobial action of the drug, but also by the site of infection, carrier system and route of 
drug delivery (Kaur et al., 2014a). Administration of oral antibiotics cause many systemic 
side effects like inadequate drug concentration reaching the pocket and decrease in the 
concentration rapidly to subtherapeutic level, requiring frequent dosing, causing patient 
incompliance and development of microbial resistance (Kataria et al., 2014). In view of the 
fact that the disease is confined to the periodontal cavity, local delivery of the drug in the 
pocket itself could be a probable choice (Garg et al., 2011d). The periodontal pocket 
simulates as a natural reservoir and provides easy admittance for the insertion of a medical 
device. Furthermore, the drug release and distribution in the whole pocket is provided by 
gingival crevicular fluid (GCF); in addition significant drug levels can be maintained in the 
GCF for extended duration. All these aforementioned characteristics make the intrapocket 
drug delivery a best choice (Jain et al., 2008). With the increased knowledge about the cause 
and pathogenesis of the disease, many types of dosage forms have been developed (Goyal et 
al., 2015; Garg et al., 2011c), as shown in the examples reported in Table I. 
In addition, periodontal research in the past few decades has attempted to systematically 
establish successful clinical procedures (defined as guided tissue regeneration procedures) to 
regenerate periodontal tissues, and the consequent tooth support, with the use of biomaterials, 











Table I. Various drug delivery approaches in the treatment of periodontitis. 
Dosage form Polymer Drug  References 
Films HPMC, Carbopol 934 Metronidazole Labib et al. (2014) 
 Gelatin  Meloxicam  Cetin et al. (2005) 
 PDLGA, chitosan Ipriflavone  Perugini et al. (2003) 
 Chitosan  Chlorhexidine gluconate  Ikinci et al. (2002) 
 Collagen  Tetracycline Minabe et al. (1991) 
Strips PCL  Tetracycline  Friesen et al. (2002) 
 Ethylcellulose Tetracycline, metronidazole Somayaji et al. (1998) 
 HPMC Chlorhexidine, doxycycline Ozcan et al. (1994) 
 HPMC, methylcellulose Doxycycline Taner et al. (1994) 
 Polyhydroxybutyric acid  Tetracycline hydrochloride Deasy et al. (1989) 
Gels Chitosan  Simvastatin Rao et al. (2013) 
 Gellan gum  Azithromycin  Pradeep et al. (2013a) 
 Xanthan Alendronate Pradeep et al. (2013b) 
 Pluronic  Simvastatin Pradeep et al. (2012a) 
 Carboxymethylcellulose Alendronate Pradeep et al. (2012b) 
Nanofibres Polylactide (PLA)  Metronidazole  Reise et al. (2012) 
 PCL  Doxycycline Chaturvedi et al. (2013) 
 Polytetrafluoroethylene (PTFE) 
Human gingival fibroblasts 
cultured on substrates Kearns et al. (2013) 
 Gelatin  
Periodontal ligament cells cultured 
on gelatin nanofibrous membrane Zhang et al. (2009) 
 
 
1.2.3 Periodontal wound healing  
Periodontal treatment aims primarily at controlling the infection and inflammation caused by 
the oral bacterial biofilm and thereby arrest progressive attachment loss, and prevents further 
disease progression, which may eventually lead to tooth loss. Preferably, the aim of the 
treatment must include regeneration of the lost periodontal attachment apparatus. This means 
that wound healing after periodontal therapy is characterized by the formation of new 
cementum with functionally oriented collagen fibres on the previously exposed or affected 
portion of the root, and simultaneously with a new alveolar bone formation, and a periodontal 
ligament with physiologic width and composition (Laurell et al., 2006).  
Recent studies suggest that the use of techniques like guided tissue regeneration (GTR) and 
the application of enamel matrix proteins (EMD) onto the exposed root result in true 
periodontal regeneration. Furthermore, the use of various growth factors and autologous 
blood concentrates for periodontal regeneration has also produced positive results, but more 
studies are needed. In general, both GTR and EMD, alone or in combination with bone grafts 
or substitutes, result in larger clinical improvements compared to conventional periodontal 
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treatment for deep intrabony and furcation Class II defects (i.e., bone loss between roots) 
(Stavropoulos et al., 2017).           
1.3 Complications in dental implant surgery 
The first introduction of dental implants dates back to 1970s, and is used in various regions of 
the mouth (Wheeler, 2009; Bornstein et al., 2008). Nowadays, implant surgery has become a 
routine therapy for the rehabilitation of completely or partly edentulous patients, but, despite 
its increasing popularity and high success rates, complications are still unavoidable and their 
management is becoming an important issue (Misch et al., 2008; Lamas Pelayo et al., 2008; 
Greenstein et al., 2008). Complications would happen either during intra-operative or post-
operative period of the surgery. 
Intra-operative complications, such as hematoma and ingestion or inhalation of mechanical 
components or instruments, can be serious as life-threatening. Other complications that take 
place during implant placements are typically associated with local damages such as nerve 
injury, adjacent teeth damage and perforations of the nasal cavity or maxillary sinus.  
Peri-implantitis, sinusitis, peri-implant mucositis, and periapical implant lesions are the 
complications often encountered after surgery. Hence, implant therapy is a complex 
procedure and the management of these complications linked with this therapy requires 
special training and experience. Table II shows a planned classification taking into 
consideration the time of events occurring during the surgery and the circumstances that 
emerge postoperatively (Annibali et al., 2008).  
 
Table II. Local complications in dental implant surgery. 
 
Early-stage complications Late-stage complications 
• Infection • Peri-implant mucositis 
• Edema  • Maxillary sinusitis 
• Ecchymoses and haematomas • Implant fractures 
• Emphysema • Failed osseointegration 
• Flap dehiscence • Bony defects 
• Sensory disorders • Peri-implantitis 
  
                                       
Moreover, postoperative pain after periodontal surgery is a common occurrence. According 
to a study, 70% of patients noticed some degree of pain following the periodontal surgery, 
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while most were only in the mild to moderate range; 44.1% of patients reported moderate 
pain; and 4.6% reported severe pain (Curtis et al., 1985). Pure mucogingival surgery was 
significantly related to pain and was 3.5 times more likely to cause pain than osseous surgery 
and 6 times more likely than plastic soft tissue surgery. The length of surgery was 
significantly linked to pain for osseous and soft tissue surgery.  
Therefore, also complications following dental surgery might benefit from local treatment 
with an appropriate dosage form. 
 
1.4 Biopolymers as wound healing materials 
Wound healing is a physiological process involving many factors, whose complexity makes it 
prone to several abnormalities. Apart from cellular and biochemical components, several 
enzymatic pathways also happen to become active during repair and aid the tissue to heal. 
The requirements of biomaterials for new therapies in regenerative medicine are vast. They 
must be biocompatible, allow vascularisation and should have good handling capabilities. 
The implant should stay at the intended site and adhere tightly to the tissue, and consequently 
can serve as excellent carrier for therapeutic agents or accelerate wound healing process.  
The polymer scaffolds which are said to be biocompatible and biodegradable combined with 
cells or biological signals are being investigated as alternatives to conventional options for 
tissue reconstruction and transplantation.  
The requirements like elasticity, tear-resistance and biodegradability can be quite different 
depending on the application. 
The common feature of all these materials is the necessity of physical protection from 
external factors and conditions. The main characteristics that are required for ideal wound 
healing materials include ease of application, bioadhesiveness to the wound surface, 
inhibition of bacterial invasion, elasticity and high mechanical strength, biodegradability and 
finally being non-toxic and non-antigenic (Balasubramani et al., 2001; Jones et al., 2002). 
A great deal of research is currently being undertaken to develop wound healing materials 
that can provide optimum healing conditions, taking into account all of these factors and 
healing mechanisms involving inflammation, tissue replacement, fibrosis, coagulation, etc. 




Figure 3. Wound healing mechanism. 
 
Many natural and synthetic polymers like collagen, hyaluronic acid and its derivatives, 
alginic acid and its salts, and fucoidan and synthetic polymers, like polyurethane, Teflon, 
silicon and methylmethacrylate, are being widely used in the preparation of artificial wound 
dressing materials. 
On the other hand, pharmaceutical formulations like natural and synthetic gel-like materials, 
composites, micro- or nanoparticulate systems, and films have been attributed profoundly in 
the development of biomaterials for wound healing and other tissue engineering purposes. 
 
1.5 Multilayer films  
A multilayer film can be defined as a film that contains two or more layers made of film-
forming polymers with one or more active substances. Over the last few years, the release of 
active substances from multilayer films has become increasingly important due to their 
efficiency in administration for local therapy as well as systemic therapy (Rupprecht and 
Zinzen, 2004) and the advantages they possess over polymeric single-layered films or 
monolithic films, like increased drug loading and controlled drug delivery. However this 
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dosage form up to now encountered serious technological difficulties since these multilayer 
films are preferably produced by a casting process. Also considerable problems arise in the 
scaling-up of the production process from the laboratory to the mass production level. 
 
1.5.1 Preparation methods of multilayer films  
Over the years, the solvent casting method is said to be the manufacturing method of choice 
for both industrial and lab scale due to its simplicity and low cost. In this method, all the 
ingredients are dissolved in a suitable solvent, then cast on an inert substrate and 
subsequently dried. The drying step can be achieved either at room temperature or in hot air 
oven or by freeze or vacuum drying.  
Alternative methods like double casting, crimping, compressing, coating and dropping have 
been used to prepare multilayer films ( Preis M et al., 2014). The processes for preparation of 




Figure 4. Preparation methods of multilayer films. 
 
In the double casting method, initially a casting solution is prepared and cast on a suitable 
substrate and subsequently dried at room temperature or in hot air oven, then a second layer 
is casted above the first layer and dried.  
Crimping method is also called as pasting or laminating. Two or three films of either similar 
or different thickness, either similar or different polymer composition, are prepared 
separately and then crimped. 
In the compression method two films are prepared separately by solvent casting and 
superimposed, while one film still has a tacky surface, as the solvent has not evaporated yet 
or the film is not completely dry. A roll is used to compress the layers onto each other, then 
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the resulting double-layer is often weighed down by a metal plate to increase adhesion of the 
two layers. 
In the dropping method, defined amounts of liquid of different aqueous and ethanol polymer 
solutions are dropped onto a film previously prepared using a computer-operated syringe. 
In the coating method, a drug-free film or a film loaded with a drug prepared by casting is 
dipped into a polymer solution containing drug or without drug, using an appropriate solvent 
that does not disintegrate the film (Deadman, 1964). With an appropriate choice of 
interfacial tensions and evaporation rate, the second polymer will form a uniform layer 
upon the other. This process is adapted to yield multilayer films with specific drug-release 
properties.  
Another method of preparing film is extrusion. Although hot-melt extrusion is comparatively 
a new technology in the pharmaceutical industry, it has been used in the production of many 
different dosage forms and its applicability in the production of films for both drug delivery 
and wound care applications has been demonstrated (Repka et al., 2000). When a multi-
layered film is involved, the different layers can be coextruded and then laminated together, 
or else each layer can be separately extruded on the previous one, and then laminated 
together. 
On the other hand, different types of printing methods like 3D printing, inkjet printing and 
flexographic printing, have recently attracted interest as emerging technologies for 
fabrication of drug delivery systems. Based on the selection of the technology, a very high 
precision in depositing a preferred ratio of active compound/s and excipients onto appropriate 
substrates can be achieved, which facilitates the preparation of single or multiple dosage 
forms with functional sophisticated features. The main ideas in the use of this type of 
technologies are to develop and fabricate pharmaceuticals in a tailored manner to meet some 
of the predicted personalization needs of patients. 
Three-dimensional (3D) printing is described as process to make 3D objects by a computer-
aided design 3D model. This method could be used for manufacturing polymeric thin films 
and multilayer films by depositing sequential layers of material. The objects that are created 
can be of virtually any shape or geometry. Many 3D printing technologies like 
stereolithography, sintering, melting, fused deposition modeling (FDM) or fused filament 
fabrication (FFF) are in existence (Maren et al.,2015).  
Also inkjet technologies can be considered as 3D techniques when three-dimensional objects 
are formed by multiple layering. The inkjet printing is used to precisely and accurately 
deposit small amounts of liquid on a substrate (like triple-coated inkjet paper, uncoated wood 
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free paper or double-coated sheet fed offset paper) based on digitally predesigned patterns. 
Thus, after the design of a printing pattern the deposition of a desired ratio of active 
pharmaceutical ingredient and excipient (so called ink formulation) onto a carrier substrate 
can be accomplished in a controlled manner (Sandler et al., 2011). And preparation of 
multiple layers can be done by depositing one or more layers on the top of the first with or 
without an intermediate base film layer. Furthermore, the printed layer can be shielded by a 
second base film layer. This will result in modified drug release profiles and protect the ink 
layer from detachment or mechanical stress during processing like cutting or packaging 
(Varan et al., 2017).  
Flexographic printing is an offset, rotary printing process. It is a highly flexible and cost-
effective alternative manufacturing method in which a drug-loaded substrate is deposited 
onto a polymeric thin film. Multilayer can be obtained by increasing the cycle of printing of 
drug-loaded substrate onto the polymeric support (Janßen et al., 2012). 
Although a variety of different film-forming techniques can be used in multilayer films, it is 
desirable to select a method compatible with the polymers chosen for the formulation, with 
the aim to obtain a flexible film (Yang et al., 2014). 
 
1.5.2 Design and choice of a multilayer film  
In order to achieve suitable properties and specific release profile from a multilayer film, an 
ideal formulation design is necessary. It can be optimized by properly establishing the ratio of 
surface area to thickness of drug release-controlling layers. This design can be affected by 
changing the ratio of the water-soluble to water-insoluble polymers. Moreover, it may be 
desirable to have one or more layers free of active substance in order to obtain controlled 
release rate of the drug. Due to the high degree of variability of the manufacturing process, 
the layer build-up is preferably carried out sequentially, preferably starting with the adherent 
layer as the initial substrate for the successive active substance-containing layers and the 
cover layer on the support surface (Rupprecht and Zinzen, 2004). 
 
1.5.3 Multilayer film applications in local drug delivery  
Formulation aspects and technological platforms in multilayer films allowed use of this 
system in different strategies for local drug delivery, like administration of multiple drugs or 
of drug eluting implants, in wound healing and tissue regeneration.  
Many examples of applications of multilayer films for local therapies have been disclosed, 
employing different film-forming techniques. 
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Sundararaj et al. (2013) designed a multilayered system that delivers multiple drugs directed 
at periodontitis treatment, produced by casting. This system includes four drugs, namely 
metronidazole, ketoprofen, doxycycline, and simvastatin, to eliminate infection, inhibit 
inflammation, prevent tissue destruction, and aid bone regeneration, respectively in four 
different layers with alternating single or double blank layers, which are said to be released in 
sequential manner for stepwise treatment of disease condition. 
Varan et al. (2017) studied a multilayer film containing anticancer and antiviral drugs, 
manufactured by inkjet printing onto an adhesive film obtained by solvent casting for local 
treatment of cervical cancer as a result of HPV infection. 
Lei et al. (2011) designed a PCL [poly(ε-caprolactone)]-based bi/trilayered film containing 
coating layer, drug reservoir layer and a backing layer for stent application in malignant 
stricture or stenosis, prepared by compression molding. This study revealed the potential of 
trilayered film in controlled drug delivery to intraluminal tumor due to its highly tunable zero 
order drug release.  
Rong et al. (2012) developed a PCL-based bilayer/trilayered film containing surface layer 
(with or without drug), drug reservoir layer and a backing layer for stent application, using a 
hot melt extrusion method. This study proved that PCL-based films co-loaded with drugs 
have great potential for anti-tumor application, due to their unidirectional and rate-tunable 
drug release characteristics. 
 
1.6 Multilayer films for local treatment of oral diseases 
Local treatment of oral cavity related diseases have been achieved by use of local drug 
delivery systems for a long time. Though these diseases are often exceptionally responsive to 
local therapy, the mouth often presents a variety of difficulties in the application of topical 
dosage forms (owing to saliva and different functions of the mouth), resulting in a short 
retention time of applied dosage forms leading to a low therapeutic efficacy. To surmount 
these limitations, today research concentrates on the development of bioadhesive 
formulations (Paderni et al., 2012). 
Recently, research on multilayer films for local drug administration in the oral cavity for 
certain indication areas, like oral cancer (Desai et al., 2011), oropharyngeal and periodontal 
infections (Tonglairoum et al., 2015) and pain (Abo Enin et al., 2016), (Juliano et al., 2008) 
has attracted considerable attention. The oral cavity is an attractive site for the delivery of 
drugs owing to the ease of administration and for its suitability for mucosal (local effect) and 
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transmucosal (systemic effect) drug administration. In the first case, the aim is to achieve a 
site-specific release of the drug on the mucosa.  
Although there are diverse techniques for the extended drug release from formulations, like 
solid dosage forms, intended for buccal applications, they have the disadvantage that the form 
of preparation gives an extraneous feel to the patient when adhered to the gingiva and 
possibly causes pain. For this reason, multilayer films are assessed as an attractive and 
feasible dosage form to overcome some negative aspects of conventional oral dosage forms.  
The properties of a film that satisfy the requirements for use in the buccal cavity are 
thickness, flexibility, mucoadhesion, control of the release of active substances and 
compatibility. 
A non-exhaustive list of papers describing the formulation of multilayer films for oral 
application is reported in Table III. 
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Table III. Multilayer films for local drug delivery in oral diseases. 
Drug substance Multilayer type Polymers  Technology Reference 
Metronidazole benzoate  2 Primary layer – chitosan Solvent casting El-Kamel et al. (2007) 
  Secondary layer - chitosan and poly(ε-caprolactone)   
Ipriflavone 3  Primary layer – chitosan Solvent casting Perugini et al. (2003) 
  Secondary layer - poly(ε-caprolactone)   
  Tertiary layer – chitosan   
Prednisolone 2 Primary layer - sodium alginate Solvent casting Ragwa et al. (2017) 
  Secondary layer - gellan gum   
  
Backing layer - ethylcellulose or white beeswax and white 
petrolatum   
N/A 2 Mucoadhesive layer - polyethylene oxide and carmellose 
sodium  
Solvent casting Danek et al. (2017) 
Imiquimod 2 Mucoadhesive layer - PVP K-90 and NaCMC Solvent casting Ramineni et al. (2013) 
  Backing layer - poly(ethylene-co-vinyl acetate)    
Phenytoin sodium 2 Mucoadhesive layer - carbopol 934, NaCMC, HPMC Solvent casting Najafi et al. (2011) 
  Backing layer - cellulose acetate phthalate    
Tetracycline hydrochloride 
and carvacrol 2 Mucoadhesive layer - carbopol 934 Solvent casting Obaidat et al. (2011) 
  Backing layer - ethylcellulose    
Chlorhexidine diacetate 2 Mucoadhesive layer - sodium alginate / HPMC / chitosan Solvent casting Juliano et al. (2008) 
  Backing layer - HPMC K100LV    
Lidocaine hydrochloride 
and diclofenac potassium 2 
Mucoadhesive layer - sodium alginate, HPMC K4M, 
chitosan N/A Abo Enin et al. (2016) 
  Backing layer - sodium alginate, HPMC K4M, chitosan    
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1.7 Choice of drug: chlorhexidine digluconate 
Chlorhexidine digluconate is a potent bactericidal and broad-spectrum antimicrobial agent. 
Functioning as an antiseptic, it is an effective bactericidal agent against all categories of 
microbes, including bacteria, yeast, and viruses. It has been extensively studied by the 
researches and is considered to be the “gold standard” antimicrobial drug in oral hygiene. 
Moreover, it is useful in many clinical disciplines, including periodontics, endodontics, oral 
surgery and operative dentistry (Medlicott et al., 1999). 
Chlorhexidine molecules being positively charged and whereas most bacteria and surface 
structures in the oral cavity, including the surfaces of teeth and mucous membranes, are 
negatively charged in nature. Chlorhexidine binds strongly to all these surface structures, 
based on the fact that the opposite charges attract. Hence, when chlorhexidine binds to 
microbial cell walls, it induces changes, damaging the surface structure, leading to an osmotic 
imbalance with consequent precipitation of cytoplasm and so causing cell death. These 
multiple effects of chlorhexidine enhance its bactericidal effect, which allows, due to the 
retention of chlorhexidine in the oral cavity, a prolonged residual antimicrobial activity for up 
to 12 hours or longer depending on the dosage and the form (Fardal et al., 1986; Schiøtt et al., 
1972). 
Chlorhexidine is safe and has an inherent advantage over antibiotics by not producing 
resistant microorganisms. As a result, chlorhexidine can be used repeatedly and over long 
periods of time. Furthermore, it destroys all categories of microbes, not just bacteria, and 
there is little risk for the development of opportunistic infections. 
However, the patient compliance with the long term use of chlorhexidine is limited by its 
unpleasant taste and tendency to stain the teeth brown. These adverse effects may possibly as 
result of use of conventional delivery systems, including mouth rinses and irrigation 
solutions, which allow contact of high concentrations of chlorhexidine (typically 0.2%) with 
taste buds and visible tooth surfaces. 
Currently, a great deal of evidence suggests that periodontitis occurs as intermittent bursts of 
disease progression combined with stable periods. As a result, only a few sites in an 
individual might show active disease at one time and require treatment (Goodson et al, 1982; 
Socransky et al., 1984). 
Therefore, chlorhexidine delivery could be targeted to oral cavity and the area surrounding 





1.8 Aims and objectives of the Ph.D. project 
The prolonged life and the recurrent use of new dental implant technologies suggest in the 
immediate future a strong demand for buccal dosage forms for the treatment of different 
dental health problems, such as treating post-implant surgery complications or chronic 
diseases like periodontitis and gingival retraction. 
Therefore, our research project has been focused on the development of a biopolymer-based 
multilayered film, which could be bioadhesive and biocompatible with the unhealthy tissue 
and simultaneously able to release the drug locally with a controlled rate.  
To this aim chlorhexidine digluconate was selected as a model drug as its local delivery in the 
mouth may improve treatment of dental-associated oral diseases if its saliva concentrations 
can be maintained at effective levels for prolonged period. 
Firstly, the idea was to develop a multilayered film consisting of a mucoadhesive layer, a 
supporting layer and a drug loaded layer which could exert a release rate control. With this 
aim, a preformulative study on film-forming polymers and a selection of the best candidates 
for the further development of a multilayer film is mandatory. 
Secondly, the selected optimized multilayer film should be characterized for its physico-
chemical properties like mucoadhesion, physical strength, and antimicrobial activity to 
prevent pathogen colonization. 
Finally, other characteristics that should be taken into consideration to optimize a multilayer 
film for wound healing applications are: the ease of preparation and application on wound 








MATERIALS AND METHODS 
2.1 Materials 
Hydroxypropylcellulose (HPC G) (Klucel, Ashland), hydroxypropylmethylcellulose (HPMC 
K750) (Hypromellose, Ashland), hydroxyethylcellulose (HEC G) (Natrosol, Ashland), 
polyvinylalcohol (Parteck SRP 80, Merck Millipore), bovine collagen peptide (MW 1000-
3000 Da) (Lapi Gelatine), edible gelatin (gel strength 166 g) (Rousselot 175 H30), bovine 
skin gelatin GLF 15 (gel strength 154 g) (Lapi Gelatine), chlorhexidine digluconate solution 
(20% in H2O) (Sigma-Aldrich), mucin from porcine stomach, type II (Sigma-Aldrich), 
disodium hydrogen phosphate dihydrate (Na2HPO4.2H2O) (Sigma-Aldrich), potassium 




2.2.1 Preformulation study 
The rationale behind conducting this preformulative study was to select the best polymers 
with film-forming properties. 
The film-forming polymers of interest for our application must feature properties like 
aqueous solubility, good flexibility without the use of plasticizers, mucoadhesive properties, 
good surface activity, availability in a wide range of viscosity types, and appropriate 
mechanical properties. 
To this aim, initially pure polymers were screened for film-forming properties using water as 
a solvent. 4.85g of solutions of appropriate polymer concentration 3%w/w, obtained by 
careful dispersion of the powder in deionized water at room temperature, were casted on 
polystyrene plate lids (diameter 18 or 23 mm) and let dry at 45 °C for 1 h. The obtained films 
were then peeled off and only the ones that met our requirements in terms of mechanical 
resistance and flexibility were evaluated for in vitro adhesion, mechanical, in vitro residence 
time, swelling and erosion index properties. 
 
2.2.2 Preparation of monolayer mucoadhesive films 
To the best film-forming polymer with mucoadhesive properties a model biopolymer like 
bovine collagen peptide (MW 1000-3000 Da) was added in different ratios like (100/0, 80/20, 
67/33, 50/50 %), and finally, the ratio that resulted in the most flexible films was selected for 
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further studies with other biopolymers like gelatin type A and B, collagen peptide (MW 5000 
Da) and a undisclosed novel product (NP) of animal origin which is supposed to have wound 
healing and anti-inflammatory properties.  
Solvent casting method was used to prepare the monolayer films. Briefly, the casting 
solutions containing 1.5% w/w biopolymers and 3.5% w/w film-forming polymer were 
prepared by dispersion of the powders in appropriate volumes of deionized water under 
continuous stirring at 37 °C. Then, the casting solutions (0.5 g of polymer solution per 
mould) were casted on polystyrene plate lids (diameter 23 mm) and dried at 45 °C for 1 h in a 
thermostated oven. Then the prepared films were evaluated for in vitro adhesion, mechanical, 
ex vivo residence time, swelling and erosion properties respectively. 
 
2.2.3 Preparation of bilayer films 
For bilayer films, a double casting method was used to prepare films: initially, polymer 
dispersions of supporting layer were cast and dried at 45 °C, then a mucoadhesive layer with 
or without drug was cast on the first layer and dried at the same temperature. The prepared 
films were evaluated for mechanical properties. 
 
Composition of bilayer films: 
(a1). Mucoadhesive layer without drug: a polymer mixture containing 3.5% w/w of HPC G 
and 1.5% w/w of novel product (NP) 
(a2). Mucoadhesive layer with drug: a polymer mixture containing 3.5% w/w of HPC G, 
1.5% w/w of NP and 0.5% w/w of chlorhexidine digluconate (CHX). 
(b). Supporting layer: a polymer mixture containing 5% w/w HPC G alone or 3.5% w/w HPC 
G and 1.5% w/w of biopolymer (like gelatin type A and B) or film-forming polymers like 
pectin, sodium alginate and sodium carboxymethylcellulose. 
 
2.2.4 Preparation of trilayer films 
Trilayer films were prepared by a double casting method (Fig. 61). Briefly, casting solutions 
were prepared by dispersing selected polymer mixtures in appropriate volumes of deionized 
water in a closed container maintained at constant homogenization (magnetic stirring, 300 
rpm) at 37 °C and at room temperature for 1 h. After complete homogenization, the casting 
solutions of the local drug delivery layer were cast (0.5 g of solution per mold) on 
polystyrene plate lids (diameter 23 mm) and dried at 45 °C in a thermostated oven for 1 h. 
Eventually, the casting solutions of supporting and mucoadhesive layers were cast and dried 
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at the same temperature for 2 and 3 h respectively. Finally, films were peeled from the mold 
and were used to evaluate their properties. 
 
Composition of trilayer films: 
(a) Mucoadhesive layer: a polymer mixture containing 3.5% w/w of HPC G, 1.5% w/w of 
novel product (NP) and 0.125% w/w of CHX. 
(b) Supporting layer: a polymer solution containing 5% w/w of HPC G alone or a mixture 
containing 3.5% w/w of HPC G, 1.5% w/w of gelatin type A and 0.25% w/w of CHX. 
(c) Local drug delivery layer: a polymer solution containing 5% w/w of HPC G alone and 
0.5% w/w of CHX, or a mixture containing 2.5% w/w of HPC G, 2.5% w/w of HEC G and 
0.5% w/w of CHX, or a mixture of 2.5% w/w of HPC G, 2.5% w/w of HPMC K750 and 














                                       Figure 6. Formulation design of trilayer films. 
 
2.2.5 Weight and thickness  
The films (n = 5) were individually weighed on a digital analytical balance (Scaltec SBC 21). 
The film thickness was measured with the help of a digital calliper (Mitituyo, Aurora) in five 
random positions of the film. The average thickness value determined was also accounted for 
mechanical tests. 
 
2.2.6 Surface morphology 
The surface morphology of a mucoadhesive layer containing a film former in combination of 
a biopolymer (collagen peptide 3K) in different ratios was tested by optical microscopy 
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(Alphaphot-2YS2, Nikon) to confirm surface texture and homogeneity. The appearance of the 
films was observed at a magnification factor of 10. Illustrative digital images were taken at 
the same time. 
 
2.2.7 In vitro mucoadhesion studies 
In vitro mucoadhesion was evaluated by measurement of detachment force (referred to 
surface area, MPa) and calculation of the work (mJ) necessary for the detachment of the film 
from a substrate mimicking the mucosal surface (porcine mucin tablets, 13 mm diameter, 250 
mg) (Fig. 7) using a material testing machine (LRX model, Lloyd Instruments) equipped with 
a 20 N load cell.  
The film was pasted on the upper support connected to the material testing machine with 
cyanoacrylate glue. A porcine disc was glued on the lower support and was wetted with 100 
μL of pH 6.8 phosphate buffer. Then the film was made to contact with the mucin tablet by 
lowering the upper support and a preload of 1 N was applied and the adhesive force was 
measured after 10 min by pulling the upper support at a speed of 0.1 mm/s.               
Results are reported as the mean of 3 determinations ± SD. Maximum detachment force is the 
maximum applied force at which the patch detaches from mucin substrate (Fig. 8). Total 
Work, calculated from the area under the force-distance curve, is a measure of the work that 
must be done to remove a film from the mucin substrate. Peak work, is calculated from the 
area measured up to the maximum applied force, whereas work of adhesion is the area before 
initiation of viscoelastic behaviour (Fig. 9). 
 
Preparation of mucin tablet 
Porcine mucin powder of 250 mg was weighed and the tablet was prepared by using a 13 




                                               









Figure 9. Schematic representation of work calculated at various points of detachment of 
film from the mucin substrate. 
 
2.2.8 Ex vivo mucoadhesion studies 
This test was performed on a material testing machine (LRX model, Lloyd Instruments) 
equipped with a 20 N load cell using three kinds of biological membranes. Firstly, the 
porcine buccal mucosa (Palem et al., 2011) was used due to its resemblance to human buccal 
mucosa. Secondly, the inverted chicken skin (Castan et al., 2015) was used to simulate the 
exposed submucosa in case of oral lesions and due to its surface homogeneity. Finally, a 
bovine liver tissue was used to simulate wounded tissue environment (Chen et al., 2014). 
The film was pasted on the upper support connected to the material testing machine with 
cyanoacrylate glue. A piece of biological tissue was glued on the lower support and was 
wetted with 20 μL of aqueous porcine mucin solution (10% w/v), then the film was made to 
contact with the biological tissue by lowering the upper support and a preload of 1 N was 
applied and the adhesive force was measured after 10 min by pulling the upper support at a 
speed of 0.1 mm/s. Finally, maximum detachment force and total work parameters were 
calculated from the resulted graph. Results are reported as the mean of 3 determinations ± 
SD.  
 
2.2.9 Mechanical properties 
Yield strength (YS), Young’s modulus (YM) and elongation at break (EB) were evaluated 
using the aforementioned testing machine equipped with mechanical grips. The film (10×10 
mm) was placed between the two grips and tensile stress (Fig. 10) was applied at a velocity of 
1 mm/min, until the film broke (Fig. 11).  
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Mechanical properties were calculated as follows: 
Yield strength (YS) = Peak stress / Film cross-sectional area 
Young’s modulus (YM) = Stress / Strain 
Elongation at break (EB) = Increase in length at break / Initial film length × 100 
 
 




Figure 11. Representation of mechanical properties measurement from resulted graph. 
 
Puncture strength was measured by letting a probe (5 mm diameter) pass with a velocity of 1 
mm/min through a film fixed on a support and calculating the force required to rupture the 
film.  
 
2.2.10 Ex vivo-residence time 
This test was performed by sticking the films to a porcine tissue, which was fixed onto a glass 
plate hung on a movable support of a modified disintegrating compendial apparatus that 
moves vertically into and back out of a beaker containing 900 mL, pH 6.8, phosphate buffer 
solution maintained at 37 °C; the time (min) taken by the film to detach by complete erosion 
was recorded. Furthermore, a list of pure polymers like NaCMC L, PVA SRP 80, HEC G, 
carbopol 971, gelatin A in the mucoadhesive layer and HPC G alone in the backing layer 
were used to compare the adhesion capacity of biopolymers that have been used in this study. 
Additionally, a well-known very adhesive polymer like polycarbophil was also used to verify 





2.2.11 In vivo residence time 
This study was carried out on 5 healthy human subjects (2 males & 3 females) by applying a 
drug-free film on gingival mucosa. Each film was attached by pressing it against the gingival 
mucosa above the canine tooth for specific period of time (10 sec). The residence time was 
measured by the time of complete erosion or detachment of the film from the buccal mucus 
membrane. 
 
2.2.12 Swelling and erosion index 
These studies were measured in pH 6.8 phosphate buffer. For this purpose, each trilayer film 
was weighed (W1) and placed on a pre-weighed Petri dish (35 mm diameter), then 4 mL of 
phosphate buffer was poured and maintained at 37 °C for 30, 60, 120 and 180 minutes. Then, 
the excess liquid around the gelled films was carefully removed by means of a pipette and the 
Petri dishes were reweighed to determine the weight of swollen film (W2) and swelling index 
(SI) was calculated. Further, the films were dried for 1 h at 60 °C and reweighed to determine 
the weight (W3) for calculating the erosion index (EI).            
                                                     SI = (W2-W1)/W1*100    




2.2.13 In vitro drug release study 
A modified version of previously used apparatus named home-made device (Baldassari et al., 
2018) was used to perform the in vitro dissolution test: a plunger of a 50 mL syringe was 
inserted into the 50 mL polypropylene tube in inverted position to exploit the plunger flange 
as support to attach the films. An accurately weighed film(surface area 2.27cm2) was then 
glued on the flange to limit the release of drug to only one side , and the plunger was moved 
to position the film in contact with the 5 or 10 ml of pH 6.8 PBS buffer solution [KH2PO4 
0.19 g, Na2HPO4.2H2O 2.38 g, NaCl 8g], so that the film was just below the liquid surface. 
The dissolution medium was kept at a constant temperature of 37.0 ±0.2 °C and under soft 
orbital shaking (200 rpm) in a Peltier chilling-heating dry bath (Torrey Pines Scientific Inc.). 
For each sampling time (30 min, 1, 2, 2.30, 3, 4, 5,6 and 24 h) three devices were used, so 
that each time point in the release curves is the mean of 3 values. Chlorhexidine digluconate 
concentration in the dissolution medium was measured spectrophotometrically (Hewlett 
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Packard 8453) at 254 nm and the drug released was expressed as percentage w/w of the drug 
content.   
Mass loss studies were performed in a similar way. The initial sample weight (W1) was 
recorded before the study, and final weight (W2) was measured after drying the eroded 
samples at 50 °C for 3 h. Percent mass loss was calculated and plotted against time. 
 
2.2.14 In vitro sterility test  
Films can be contaminated easily, which can lead to further infection when applied on 
wounded sites. Hence, a sterility test was performed on films employing two methods: 
(i). Incubation on rich medium agar plates: each sample was placed aseptically on Columbia 
Agar plates (Oxoid) and incubated overnight at 37 °C. Plates were then carefully examined 
for visible growth and reincubated for 48 h for regrowth. 
(ii). Incubation in nutrient broth medium: each sample was placed aseptically in 5 mL of 
Triptic Soy Broth (Biolife) and incubated overnight at 37 °C. Following that time, 20 μL 
from each culture broth were seeded on Columbia Agar plates and incubated overnight at 37 
°C. Plates were then carefully evaluated for visible growth. Samples were subsequently kept 
at 37 °C for 14 more days and re-seeded on Columbia Agar plates. 
Preparation procedure for films to be tested for sterility 
Mainly four kinds of formulations like pure films made of HPC, films made of a solution of  
5% w/w HPC pre-sterilized in autoclave, HPC+NP and HPC+NP+CHX were tested for 
sterility. Initially, all predefined polymers were weighed, placed in Petri dishes, positioned 
under a vertical laminar flow hood and finally UV sterilized overnight. The casting solutions 
were prepared in sterile vials. The polymer dispersions were prepared by adding sterile water 
and polymers into individual vials under continuous stirring by using a stirrer under the 
laminar flow hood for 1 h. Then, film formulations were casted (0.5 mL, equivalent to 0.5 g) 
on sterile polystyrene mould (18 mm) using a pipette and left to dry for 4 h. The dried films 
were exposed to UV light overnight, and finally carefully collected using sterile tweezers and 
placed in self-lock bags for sterility testing. 
 
2.2.15 In vitro blood compatibility test: whole blood clotting 
The films (2.54 cm2) to be tested were placed into plastic dishes, and pre-warmed to 37 ˚C. 
Then 0.2 mL of whole blood [BD® vacutainer ACD type A (trisodium citrate 22 g/L, citric 
acid 8 g/L, dextrose 24.5 g/L)] was then dispensed onto the surface of the samples, and 50 μL 
of 0.2 M CaCl2 solution were added to start coagulation. Subsequently, the plastic dishes  
33 
 
were placed at 37 ˚C in an incubator. After 10 min, red blood cells (RBCs) that were not 
trapped in the clot were hemolyzed with 10 mL of deionized water and centrifuged at 100 g 
for 30 s. Then 5 mL of supernatant were transferred carefully in to a tube and 20 mL of pure 
water were added. The absorbance of the resulting hemoglobin solution was measured at 542 
nm (Ds), and the absorbance of 0.2 mL whole blood hemolyzed with 25 mL deionized water 
at 540 nm was denoted as D0. The blood clotting index (BCI) was calculated with the 
formula  
 
                                               Blood clotting index (BCI) = Ds / D0 
 
2.2.16 Biological study 
THP1 cells were maintained in RPMI medium at 37 °C with 5% CO2, where culture medium 
was supplemented with 10% heat-inactivated fetal bovine serum (FBS), without antibiotics or 
antifungine supplements. 
For viability/proliferation indexes and RT-PCR, about 3 × 104 and 5 × 105 THP1 cells were 
seeded in each well of 96-microwell plates and 75 cm2 tissue flasks, respectively. After 24 h, 
THP1 were exposed to Lipopolysaccharide (LPS) alone, NP + LPS and NP alone, at a final 
dose of 3 mg/mL for NP and 5 µg/mL for LPS in complete growth medium for 6 and 24 h. 
LPS was added to the experimental medium as a positive control for monocyte activation. 
LPS, from Gram-negative bacteria, is commonly considered as one of the most potent innate 
immune-activating stimuli known. Gene expression of IL -1 and IL-8, chemokines produced 
by macrophages, was confirmed by RT-PCR. Whereas, NFkB, a transcription factor for 
damage response/adaptation genes, including inflammation and wound repair was confirmed 
by Western Blot. 
MTS assay (CellTiter 96® Aqueous One Solution Cell Proliferation Assay, Promega), a 
colorimetric method, was used for testing any cytotoxic effects of the compounds and in 
parallel for measuring cell proliferation. It contains a tetrazolium compound [3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner 
salt] and an electron coupling reagent (phenazine ethosulfate, PES). The MTS was 
bioreduced by mithocondrial dehydrogenase enzymes into a colored formazan in 
metabolically active cells. MTS can be used to point out toxicity as well as proliferation, 
since the amount of formazan is time-dependent and proportional to the number of viable 
cells. The absorbance of formazan was measured in a microtiter plate-reader at 490 nm 
(Uniskan II, Labsystem). The potential toxicity of each treatment was extrapolated and 
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expressed as percentage vs. untreated LPS-stimulated cultures, respectively for toxicity and 
proliferation index, and presented as mean ± SD of three independent experiments with three 
replicates for each concentration.  
 
2.2.17 Wound healing assay 
To study cell migration in vitro, human keratinocytes HaCat cell line was used. 8.5x105 
cells/well were seeded and grown in DMEM medium supplemented with 10% fetal bovine 
serum at 37 °C with 5% CO2, without antibiotics or antifungine supplements until a confluent 
monolayer was obtained. Then a scratch was created with a p200 pipet tip. To remove the 
debris and smooth the edge of the scratch, cells were washed once with PBS. Finally cells 
were added with medium with 10% FBS (positive control) or with medium alone (negative 
control) or treated with 3 mg/mL of NP in DMEM with 10% FBS. At time 0 and after 24 and 
48 h cell images were acquired with a phase-contrast microscope and the distance of the 
scratched region was measured. For each image, distances between one side of scratch and 
the other were detected using Image J software. By comparing the images from time 0 to the 
last time point (24, 48 hours), the distance of each scratch closure was obtained on the basis 
of the distances that were measured by software to determine the migration of cells. Each 
experiment was performed with four replicates. 
Wound closure % = (W0-Wt)/W0× 100 
W0 represents the initial width of scratching, Wt represents scratching width t hours after test 
start. 
  
2.2.18 Statistical analysis 
Statistical analysis was performed by one-way analysis of variance (ANOVA). A post hoc 
comparison test of the means of individual groups was performed using the Tukey’s HSD 
test. Statistical significance was set at p<0.05. Statistical evaluation of data was measured by 






RESULTS AND DISCUSSION 
3.1 Design of multilayer film 
Technological purposes of multilayer films were studied to retain the dosage form in the site 
of application for prolonged time and to deliver one or more active substances. The adhesion 
properties of the polymer film depend on its composition, which in principle can be adjusted 
by carefully selecting polymer components. Moreover, an ideal film, apart from having good 
mucoadhesion, should be flexible, elastic, and strong enough to withstand breakage due to the 
stress endured during its residence in the mouth. In addition, controlled drug release from a 
film with the aforementioned properties still remains a challenge. 
Therefore, in the present study, a mucus-membrane adhering multilayer film (Fig. 12) 
containing a mucoadhesive layer, a supporting layer and a local drug delivery layer has been 
rationally designed to act as a promising platform for wound healing applications in oral 
diseases. 
The formulation was preceded by a preformulation step, allowing to choose the best polymer 
compositions for each layer and testing their properties. 
                                  





Firstly, adhesive layer consists of a mucoadhesive polymer in combination with active 
substance having wound healing or anti-inflammatory properties. This layer has also a 
barrier-function to protect the wound or injury from the oral environment. This layer must not 
be irritating to the tissues or inhibit the coagulation process. 
Secondly, the supporting layer consists of a polymeric mixture containing a film-forming 
agent with texture function, favoring the fabrication process, the mechanical properties of the 
final dosage form and counteracting the erosive action of the saliva. 
Finally, the backing layer can contain polymer mixture to control the release of drug locally 
into the oral cavity, to prevent bacterial infection of the wounded site favoring the healing 
process. 
Different substances having wound healing properties like collagen peptide, gelatin type A 
and B, have been tested in this thesis, while as model drug of antimicrobial substance the 
widely used chlorohexidine digluconate has been used. 
 
3.2 Casting procedure of monolayer films 
The solvent casting method was chosen to prepare monolayer films. It is a widely used 
manufacturing process for making films, well-known by its relative simplicity and the low 
cost that the system setup requires at a research laboratory scale (Morales et al., 2011). 
In this method, monolayer films were successfully prepared by casting single aliquots of 
polymeric solutions on a polystyrene mold using a pipette (Fig. 13). Casting single aliquots 
would provide exact information about the amount of polymer and drug that has been cast 
and it does not require cutting the obtained film into pieces. Moreover, films produced by this 
method show good uniformity in the weight and thickness (Parodi et al., 2017).  
Good homogenization of polymer dispersions was obtained by mixing the polymers at 37 °C 
and room temperature. To remove the air bubbles from the solution, it was further maintained 
at room temperature at rest for at least for 2-3 h before casting.  
The casted films were dried in hot air oven at 45 °C. The prepared films were then peeled off 




                                              
                                      
                Figure 13. Photo of a PS plate with twelve 18 mm pre-printed circular edge molds. 
 
3.3 Preformulation study 
The list of polymers studied is reported in Table IV. 
Monolayer films casted with these polymers were evaluated for: 
 
• flowability of casting solution  
• structure and appearance of films  
• adhesion on mucin tablet 
• tensile stress-strain behavior 
• in vitro residence time 
• swelling index 
• erosion index 
 
3.3.1 Film properties 
A number of potential film-forming polymers (Table V), suitable for casting from aqueous 
solution, were evaluated. The resulting films were studied for rheological properties of the 
casting colloidal solutions, shrinking tendency, ease of removal from the mold 
(detachability), rigidity/flexibility, thickness, transparency and texture smoothness.     
Some water soluble, natural film-forming polymers, like sodium alginate and pectin resulted 
in rigid films (0.1 mm) not suitable for application on anatomic irregularities of gingival 
mucosa. 
Furthermore, some cellulose-based polymers like NaCMC and low viscosity grades of PVP, 
like K30 and K64, produced rigid films. Though few polymers like PVP K90 and PEO-PVA 
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copolymers were flexible, the resulting films were too thin (0.02 mm). Therefore, these 
polymers were not considered for further studies. 
Among the tested polymers, modified cellulosic polymers like hydroxypropylcellulose 
(HPC), hydroxypropylmethylcellulose (HPMC), hydroxyethylcellulose (HEC) and synthetic 
polymers like polyvinylalcohol (PVA) permitted to produce films with good flexibility 
without the use of the plasticizer agents (i.e. glycerin) and for this reason have been selected 
as possible candidates for the next steps of the preformulative evaluation.  
 
Table IV. List of polymers used and their abbreviation and viscosity 
Abbreviation Polymer Viscosity(mPa*s) Solution conc (%) Brand 
PVA SRP 80 Polyvinyl alcohol 34-46 4 Parteck SRP 80 
PVA Mowiol 4-88 Polyvinyl alcohol 3.5-4.5 4 Mowiol 4-88 
HEC G Hydroxyethyl cellulose 250-400 2 Natrosol G Pharm 
HEC H Hydroxyethyl cellulose 3,500-5,500 1 Natrosol H Pharm 
HEC L Hydroxyethyl cellulose 75-150 5 Natrosol L Pharm 
HPC G Hydroxypropyl cellulose 150-400  2 Klucel GF 
HPC M Hydroxypropyl cellulose 4,000-6,500 2 Klucel MF 
NaCMC L Sodium carboxy methyl cellulose 25-30 2 Blanose 7LP EP 
NaCMC M Sodium carboxy methyl cellulose 200-800 2 Blanose 7M8SF PH 
PVP VA 64 Polyvinylpyrrolidone 8 10 Kollidon VA 64 
PVP 30 Polyvinylpyrrolidone 5.5-8.5 10 Kollidon 30 
PVP 90 F Polyvinylpyrrolidone 300-700 10 Kollidon 90 F 
HPMC E15 Hydroxypropyl methylcellulose 12-15 2 Methocel E15 LV 
HPMC E3 Hydroxypropyl methylcellulose 2.4-3.6 2 Methocel E3 
HPMC K15 Hydroxypropyl methylcellulose 13,275-24,780 2 Methocel K15 
HPMC K100 LV Hydroxypropyl methylcellulose 80-120 2 Benecel K100LV 
HPMC K250 Hydroxypropyl methylcellulose 200-300 2 Benecel K250 
HPMC K750 Hydroxypropyl methylcellulose 562-1050 2 Benecel K750 
PEO WSR N-80 Polyethleneoxide 55-90 5 Polyox WSR N-80 
PEO WSR N-12K Polyethleneoxide 400-800 2 Polyox WSR N-12K 
PEO WSR N-60K Polyethleneoxide 2,000-4,000 2 Polyox  WSR N-60K 
MC A15 Methyl cellulose 12-18 2 Methocel A15 
MC A4M Methyl cellulose 2,663-4,970 2 Methocel A4M 




Table V. List of polymers tested for film-forming properties. 
Polymers  Flexibility/Rigidity Detachability  Appearance 
PVA  SRP 80 Flexible Detachable Transparent 
HEC G  Flexible  Detachable Transparent 
HPC G   Flexible  Detachable Transparent 
Pectin LM  Rigid  Detachable Translucent 
Pectin HM   Rigid  Detachable Translucent 
NaCMC L  Rigid  Detachable Transparent 
NaCMC M   Rigid  Detachable Transparent 
Sodium alginate  Rigid  Detachable Translucent 
PVP K64   Brittle Undetachable N/A 
PVP K90  Flexible Detachable Transparent 
PVP K30   Brittle  Undetachable Transparent 
HPMC E15  Flexible  Detachable Transparent 
HPMC E3  Flexible  Detachable Transparent 
HPMC K15  Too viscous to cast N/A N/A 
PEO WSR N-80  Flexible  Detachable Translucent 
Methyl cellulose A15  Partially flexible to rigid  Detachable Transparent 
Methyl cellulose A4M  Partially flexible to rigid  Detachable Transparent 
Polaxomer 407  Brittle  Undetachable N/A 
PEO WSR N-12K  Flexible  Detachable Translucent 
PEO WSR N-60K Flexible but Shrunken Detachable Translucent 
Carbopol 971  Too viscous to cast N/A N/A 
Polaxomer 407  Brittle  Detachable Translucent 
HPSP  Flexible  Detachable Translucent 
Kollicoat  IR  Flexible  Detachable Translucent 
Kollicoat PROTECT  Flexible  Detachable Translucent 
PVA Mowiol 4-88 Flexible  Detachable Translucent 
HPC M  Too viscous to cast N/A N/A 
HPMC K100 LV  Flexible  Detachable Translucent 
HEC H  Too viscous to cast N/A N/A 
HPMC K250   Flexible  Detachable Translucent 
HPMC K750   Flexible  Detachable Translucent 






3.3.2 Adhesion on mucin tablet 
This study has been performed using porcine mucin tablet as a substrate (Fig. 14). In Fig. 15 
the maximum detachment force of films made of pure polymers are compared. HPC G and 
the two grades of PVA showed higher adhesion force compared to HEC G and HPMC K750. 
Whereas, work of adhesion (Fig. 16) was higher for HPC, HPMC and PVA based polymers  










Figure 15. Comparision of maximum detachment force (MPa) of pure polymers tested on 




Figure 16. Adhesion properties of prepared films: work of adhesion (mJ) of pure polymers 




3.3.3 Tensile stress-strain behavior  
The mechanical properties of the prepared films were tested using the same material testing 
machine, but with different equipment (Fig. 17). Figure 18 shows yield strength of the pure 
polymers tested. HPMC K750 and HPMC E15 showed good yield strength, whereas other 
polymers, like HPC G, the two grades of PVA and HEC, showed low yield strength: these 
polymer films, at a low stress, got deformed. 
 
 
Figure 17. Illustration of material tester to measure tensile stress-strain curve of the films. 
 
Figure 19 shows the Young’s modulus comparison of the tested pure polymer film. The films 
made of pure HPC showed the most elastic behavior. This elastic nature of the polymer was 
well correlated with the results of the elongation at break (Fig. 20). Though films of PVA 
Mowiol 4-88 showed a low Young’s modulus, its elasticity was poor as measured by the 
elongation at break value. 
 
3.3.4 Swelling Index  
Swelling index was measured on pure polymers by using the Petri dish method (Khan S et al., 
2016) (Fig. 21) and using pH 6.8 phosphate buffer as the medium. The SI values comparison 
(Fig. 22) shows that HPMC K750 and HPMC E15 reached the highest  value, while the two 




3.3.5 Erosion Index  
The erosion study results of the pure polymer films, performed in pH 6.8 phosphate buffer 
medium, are reported in Fig. 23. Among all the polymers tested, HPC G, HPMC K750 and 
HPMC E15 showed the lowest erosion index, while PVA type Mowiol 4-88, because of its 
lower viscosity and high solubility, showed the highest EI.   
 
 
Figure 18. Mechanical properties of prepared films: yield strength (MPa) of pure polymers 
tested on material testing machine; (values represented as mean (n = 3) and with error bar 





Figure 19. Mechanical properties of prepared films: Young’s modulus (MPa) of pure 
polymers tested on material testing machine; (values represented as mean (n = 3) and with 
error bar representing standard deviation). 
 
 
                         
Figure 20. Mechanical properties of prepared films: Elongation at break (%) of pure 
polymers tested on material testing machine (values represented as mean (n = 3) and with 










Figure 22. Swelling behavior of the prepared films tested in pH 6.8 phosphate buffer (values 





Figure 23. Erosion behavior of the prepared films tested in pH 6.8 phosphate buffer (values 
represented as mean (n = 3) and with error bar representing standard deviation). 
 
 
3.3.6 Residence time  
In vitro residence time study was performed by a modified disintegration apparatus using a 
glass slide as support (Fig. 24). Time comparison (Fig. 25) shows that HPC G polymer films 
remained attached for the longest time with respect to the other polymeric films, followed by 
HPMC K750. PVA and HEC based films showed the lowest residence time, probably due to 




Figure 24. Modified compendial disintegration apparatus used to study residence time. 
 
 
Figure 25. In vitro residence time of the pure polymer films tested by modified disintegration 
apparatus in pH 6.8 phosphate buffer (values represented as mean (n = 3) and with error bar 





4. Selection of mucoadhesive layer 
The first layer, which will be in contact with mucus membrane, must have the following 
characteristics: good mucoadhesive property, low SI and EI, good residence time and high 
mechanical resistance 
HPC was selected as the best candidate for the mucoadhesive layer, because it showed all 
these properties. 
Over the years, natural biopolymers like collagen, hyaluronic acid and derivatives have been 
used for wound healing applications (Table.VI). 
 
Table VI. List of natural polymers used in wound healing. 
Biopolymer Source Uses Reference 
Collagen Bovine, pig skin 
Many biomedical applications like 
wound dressing materials and hemostatic 
Hafemann et 
al., 1999 
Alginic acid and 
its salts 
Natural polysaccharide 
derived from brown algae 







Mammal’s bond tissues and 
synovial fluids 
Acceleration of tissue repair and wound 
healing 
Saliba et al., 
2001 
Chitosan 
Shells of shrimp and other 
crustaceans 
Treatment of wounds due to its 
hemostatic effect 
Senel et al, 
2004 
Fucoidan 
Many species of brown 
seaweed 





The properties of layer films obtained by combining the selected HPC polymer with 
biopolymers like collagen peptide (MW 1000-3000 Da and MW 5000 Da), gelatin type A, 
gelatin type B and a novel product of animal origin (NP), used for their anti-inflammatory 
and wound healing properties, were studied. 
 
The NP used in the study is an animal extract containing, among other minor components, 
hyaluronic acid, collagen, elastin and chondroitin-4-sulphate, for which an anti-inflammatory 
and wound healing activity has been demonstrated in the biological study here reported. 
 
4.1 Biological study on NP 
4.1.1 Anti-inflammatory activity  
In this study, the viability and proliferation of THP1 cells in the presence of NP were 
measured using the MTS assay, while proinflammatory cytokine gene expression was 
determined using RT-PCR mRNA. The obtained data of the viability index, extrapolated by 
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the MTS assay revealed that the exposure to NP at the tested doses did not exert toxicity on 
THP1 cells (Fig. 26) with respect to LPS treatment. Especially with athe dose of 3 mg/mL, 
the viability of the cells seems to be stimulated in a time-dependent way. 
THP1 activation, after adding LPS, was assessed in terms of modulation of IL-1β and IL-8 
gene expression, as representative of proinflammatory chemokines synthesis. LPS induced 
the expression of IL-1β and IL-8 in untreated cultures, both at 6 and 24 h (Figs.27 and 28), 
while NP exposure demonstrated a protective role of this extract. 
In addition, NF-kB, which has a fundamental role in inflammatory condition to eliminate the 
initial cause of damage and to promote the process of repair of the involved tissue, has been 
studied. From the results, reported in Fig. 29, the increase in the ratio of phosphorylated 




Figure 26. MTS assay performed on THP1 cell line treated with NP (values represented as 




                              
             Figure 27. Study of IL-1 expression at 6 and 24 h(values represented as mean (n = 3) 
and with error bar representing standard deviation). 
 
  
                                    
            Figure 28. Study of IL-8 expression at 6 and 24 h (values represented as mean (n = 3) 







               Figure 29. Study of NFkB expression at 24 h(values represented as mean (n = 3) 
and with error bar representing standard deviation). 
 
 
4.1.2 Wound healing assay 
The cell wound closure assay examines the ability of a particular cell line to migrate and 
subsequently close a wound made in a confluent plate of cells. As shown in Figs. 30, 31, 32, 
the migration of keratinocytes into the wounded area was distinctly increased in the presence 
of NP 3 mg/mL. In particular, the effect is clearly evident at 24 h after the treatment, where 





Figure 30. Effect of NP on migration of keratinocytes at different incubation times (0, 24 and 
48 h) (values represented as mean (n = 3) and with error bar representing standard deviation). 
 
 
Figure 31. A scatter plot was used to display the width of the wound over time and 
the rate of wound closure in the presence of NP 3 mg/mL was calculated. To generate 
the r2 value, a linear regression was run on the wound width data. 






















Figure 32. Quantitative analysis of wound healing for cell cultures incubated with positive 
control (FBS), negative control (without FBS), and NP treated (values represented as mean (n 
= 3) and with error bar representing standard deviation). 
 
4.1.3 Blood clotting index 
The first layer applied on wound must be protective and not inhibit blood coagulation. The 
blood clotting index of pure NP and of film composition containing HPC+NP and film of 
pure HPC were evaluated on whole human blood by a clotting experiment. PTFE and an 
insoluble NP were used as substrates and medical gauze as control. Human whole blood was 
allowed to contact with all the substrates used and then an amount of Ca2+ ion was added to 
promote coagulation. Then, the RBCs not trapped in clots were haemolysed by adding 25 mL 
of ultrapure water. The absorbance at 540 nm is related to the concentration of haemoglobin 
passed in solution from lysed free RBCs: a lower BCI value indicates a better blood clotting 
capability. BCI values of insoluble NP, NP coating the insoluble NP used as substrate and of 
the medical gauze were 0.03±0.014, 0.18±0.07 and 0.10±0.009, respectively. From Fig. 33, it 
is clear that NP has not a negative effect on blood clotting, while HPC inhibits blood clotting 






















Figure 33. Blood clotting index. PTFE/NP denotes NP deposited on PTFE, Insoluble NP/NP 
denotes NP deposited on insoluble NP (values represented as mean (n = 3) and with error bar 
representing standard deviation). 
 
These biological tests confirmed the anti-inflammatory and wound healing properties of NP.  
As said, after the biological tests, the selected best candidate from the preliminary study 
(HPC G) was combined with different biopolymers and was investigated for further 
properties. 
 
4.2 Formulation study of first layer 
The morphological characteristics of monolayer films produced are listed in Table VII. 
 
Table VII. Physical characteristics of monolayer films. 
Monolayer film Thickness (mm)* Weight (mg)* 
HPC G 0.057 ± 0.012 25.6 ± 0.5 
COLL PEP 3K + HPC G  0.052 ± 0.008 26.1 ±1.0 
COLL PEP 5K + HPC G  0.058 ± 0.010 25.7 ± 1.2 
NP + HPC G  0.053 ± 0.006 26.2 ± 1.1 
GEL A + HPC G  0.055 ± 0.009 25.9 ± 0.7 
GEL B + HPC G 0.060 ± 0.010 25.5 ± 0.4 




4.2.1 Surface morphology  
The feasibility and film forming nature of film formers with biopolymers in different ratios 
was tested by optical microscopy to confirm surface texture and homogeneity. It was evident 
that HPC G polymer maintained its film-forming property when ≥50% collagen peptide was 
added, but its mechanical properties were weak as cracks and surface roughness can be seen 
in the relevant microscopic images (Fig. 34). Hence, a mixture of HPC/collagen peptide 3K 
(70% / 30%) ratio was used for further studies.  
 
 
Figure 34. Surface morphology of films with different ratio of % collagen peptide / % HPC 
G. 
 
4.2.2 Adhesive behavior 
Figures 35-36 report the adhesive properties of the HPC polymer combined with different 
biopolymers. It was evident that the addition of NP had no negative effect on the detachment 
force of HPC (p>0.05) (Fig. 35) and, furthermore, increased the total work of adhesion. 
Whereas, other biopolymers seem to have a tendential negative effect on maximum 
detachment force of the HPC polymer and no considerable effect on total work (p>0.05) (Fig. 





Figure 35. Adhesion properties of prepared films: maximum detachment force (MPa) of 
HPC and biopolymer mixtures tested on mucin tablet (values represented as mean (n = 3) and 
with error bar representing standard deviation). 
 
 
Figure 36. Adhesion properties of prepared films: work of adhesion (mJ) of HPC and 
biopolymer mixtures tested on mucin tablet (values represented as mean (n = 3) and with 




4.2.3 Mechanical properties  
Mechanical properties of prepared films are shown in Figs. 37-39. From Fig. 37 it can be 
observed that the addition of collagen peptide 3k, collagen peptide 5k and NP to HPC had a 
negative effect on the yield strength, while gelatin type A and B did not show any significant 
effect. 
The addition of biopolymers increased the rigidity of the HPC based film as shown in Figure 
38 and confirmed by the clear reduction of the elongation at break of these films (Fig. 39). 
 
 
Figure 37. Mechanical properties of prepared films: yield strength (MPa) tested on material 





Figure 38. Mechanical properties of prepared films: Young’s modulus (MPa) tested on 




Figure 39. Mechanical properties of prepared films: elongation at break (%) tested on 




4.2.3 Swelling and erosion properties  
The addition of the considered biopolymers had not a significant effect on the swelling 
behaviour of the HPC-based films (Fig. 40). On the other hand, the erosion index (Fig. 41) 
increased in the presence of both grades of collagen peptides and NP (p<0.05). Conversely, 
gelatin type A and B slightly decreased the erosion compared to pure HPC film. The 
reduction in erosion might be due to the low solubility of gelatine at 37 °C. 
 
 
Figure 40. Swelling behavior of the prepared films tested in pH 6.8 phosphate buffer (values 





Figure 41. Erosion behavior of prepared films tested in pH 6.8 phosphate buffer (values 
represented as mean (n = 3) and with error bar representing standard deviation). 
 
4.2.4 Ex vivo residence time  
These films were tested for ex vivo residence time (Fig. 42) using porcine mucosa substrate in 
the apparatus described in Fig. 24. The pure HPC film showed the highest residence time 
equal to about 2 hours. The addition of biopolymers to HPC films led to a strong reduction in 
the residence time, with HPC+collagen peptide 5k having the lowest time measured, equal to 
only 2.2 minutes. 
The films tested can be divided into 3 classes of behavior for residence time:  
1) Over 60 min (HPC alone) 
2) Between 30-60 min (HPC+collagen peptide 3k, HPC+NP, HPC+geatin A, 
HPC+gelatin B) 





Figure 42. Ex vivo residence time of the prepared films tested using porcine mucosa as a 
substrate (values represented as mean (n = 3) and with error bar representing standard 
deviation). 
 
The experiment was replied using a HPC layer as a support of the previous mixtures, 
observing a net increase of the residence time (Fig. 43). Notably, for the HPC+NP/HPC film 
residence time increased to 180 min. Furthermore, the addition of the model drug 
chlorhexidine digluconate (CHX) increased the residence time further to 410 min. This effect 
could be explained considering the possible electrical interaction between mucin (anionic) 





Figure 43. Ex vivo residence time of the prepared films containing HPC as back support 
tested using porcine mucosa (values represented as mean (n = 3) and with error bar 
representing standard deviation). 
 
5. Selection of supporting layer 
From the studies performed on the first layer it was evident that NP did notshow any negative 
effect on adhesion, but it weakened the mechanical properties of the HPC polymer.  
Therefore, a support layer was required for giving texture to the entire multilayer structure. 
To this aim, polymer combinations of HPC and those polymers that gave rigid films when 
used alone were studied: HPC+gelatin A, HPC+gelatin B, HPC+pectin, HPC+sodium 
alginate, HPC+NaCMC were tested as a second or support layer, with the aim to enhance the 
mechanical properties. 
 
5.1 Formulation study of second layer 






Table VIII. Physical characteristics of bilayer films. 
Bilayer film composition     
First layer Second layer Thickness (mm)* Weight (mg)* 
HPC+ NP HPC+GELA 0.118 ± 0.018 51.8 ± 1.1 
HPC+ NP HPC+GELB 0.116 ± 0.018 52.2 ± 0.4 
HPC+ NP HPC+Pectin 0.124 ± 0.021 51.4 ± 1.3 
HPC+NP HPC+Sodium alginate 0.112 ± 0.026 51.4 ± 1.3 
HPC+ NP HPC+NaCMC 0.116 ± 0.011 51.9 ± 1.1 
HPC+ NP HPC 0.110 ± 0.007 51.9 ± 1.1 
*values represented as mean ± S.D. (n = 3) 
 
5.1.1 Mechanical properties 
In Figures 44-48 the mechanical properties of the bilayer films tested are reported. 
The yield strength (Fig. 44) of the films containing HPC+pectin, HPC+sodium alginate and 
HPC+NaCMC was slightly increased, in comparison with the other films tested, but these 
films were too rigid: in fact, films with HPC+GELA, HPC+GELB showed higher elasticity 
(Fig. 45) with respect to the aforementioned combinations. HPC+GELA was slightly more 
elastic and had higher yield strength if compared to HPC+GELB. 
Due to their elastic nature, elongation at break (Fig. 46) was higher for films containing 
HPC+GELA, HPC+GELB, while HPC+pectin, HPC+sodium alginate and HPC+NaCMC 





Figure 44. Mechanical properties of prepared films: yield strength (MPa) tested on material 





Figure 45. Mechanical properties of prepared films: Young’s modulus (MPa) tested on 





Figure 46. Mechanical properties of prepared films: elongation at break (%) tested on 
material testing machine (values represented as mean (n = 3) and with error bar representing 
standard deviation). 
 
In addition, the results of puncture strength (Fig. 47) showed that the films with HPC+GELA, 
HPC+GEL B got ruptured at higher load compared to HPC+pectin, HPC+sodium alginate 
and HPC+NaCMC as support layer, and this behavior can be related to the elastic nature of 
these films (Fig. 48). 
In the end, based on the results obtained from the previous study of mechanical properties, 





Figure 47. Puncture strength equipment using material testing machine. 
 
Figure 48. Mechanical properties of prepared films: puncture strength (N) tested on material 
testing machine using 5 mm probe (values represented as mean (n = 3) and with error bar 
representing standard deviation). 
 
6. Selection of third layer 
The third layer or backing layer was planned to control the release of antimicrobial drug .To 
this aim, for continuing the study we selected HPMC K750, HEC G and HPC alone, which 
are film-forming agents but also known for their ability to control the drug release. 
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The tested trilayer films were prepared by double casting method. The prepared films were 
evaluated for adhesion, mechanical, residence, swelling, erosion and in vitro drug release 
properties. 
 
6.1 Formulation study of third layer 
The morphological characteristics of trilayer films studied are listed in Table IX. 
 












HPC (70%)+NP(30%) HPC(100%) HPC(100%) 0.164 ± 0.013 75.6 ± 1.34 
HPC (70%)+NP(30%) HPC(70%)+GELA(30%) HPC(50%)+HEC(50%) 0.166 ±0.011 75.4 ± 0.90 
HPC (70%)+NP(30%) HPC(70%)+GELA(30%) HPC(50%)+HPMC(50%) 0.162 ±0.008 75.2 ± 0.59 
                                   *values represented as mean ± S.D. (n = 5) 
 
6.1.1 In vitro adhesion properties 
Figures 49-53 show in vitro adhesion properties of the prepared trilayer films on mucin 
substrate.  
The results of max detachment force (Fig. 49) show that there is a slight increase in adhesion 
in films containing HPMC and HEC as third layer compared to films with HPC alone as third 
layer. However, the difference is not significant (p>0.05).  
Even in the case of total work (Fig. 50), peak work (Fig. 51) and work of adhesion (Fig. 52) 
there is no significant difference (p>0.05) among the prepared trilayer films, when three 





Figure 49. Adhesion properties of prepared films: maximum detachment force (MPa) of a 
trilayer film tested on mucin tablet (values represented as mean (n = 3) and with error bar 
representing standard deviation). 
 
 
Figure 50. Adhesion properties of prepared films: total work (mJ) of trilayer films tested on 





Figure 51. Adhesion properties of prepared films: peak work (mJ) of trilayer films tested on 




Figure 52. Adhesion properties of prepared films: work of adhesion (mJ) of trilayer films 







6.1.2 Ex vivo mucoadhesion studies 
Three different kinds of biological substrates were used for ex vivo mucoadhesion study (Fig. 
53): porcine buccal mucosa, which mimics the human buccal tissue, the inverted chicken 













The results of ex vivo mucoadhesion study on porcine mucosa (Fig. 54) show that the 
maximum detachment force (Fig. 55) increased for films containing HPC+HEC as third layer 




Figure 55. Adhesion properties of prepared films: maximum detachment force (MPa) of 
trilayer films tested on porcine mucosa (values represented as mean (n = 3) and with error bar 
representing standard deviation). 
 
 
Figure 56. Adhesion properties of prepared films: total work (mJ) of trilayer films tested on 




Secondly, ex vivo mucoadhesion was tested on inverted chicken skin as biological substrate 
(Fig. 57). 
 
Figure 57. Equipment for ex vivo mucoadhesion tested on inverted chicken skin as biological 
substrate. 
 
On inverted chicken skin the results showed that the maximum detachment force (Fig. 58) 
was slightly increased in films containing HPC+HEC as the third layer. Whereas, for total 
work (Fig. 59), no considerable differences were observed among the films tested. 
 
Figure 58. Adhesion properties of prepared films: max detachment force (MPa) of trilayer 
films tested on inverted chicken skin (values represented as mean (n = 3) and with error bar 




Figure 59. Adhesion properties of prepared films: total work (mJ) of trilayer films tested on 
inverted chicken skin (values represented as mean (n = 3) and with error bar representing 
standard deviation). 
 
Finally, ex vivo adhesion was tested on liver tissue to simulate the wounded environment 
(Fig. 60). 
 
Figure 60. Equipment for ex vivo mucoadhesion tested on bovine liver tissue as biological 
substrate. 
 
The results demonstrate that among the prepared trilayer films tested, maximum detachment 
force (Fig. 61) and total work (Fig. 62) were not significantly different. But comparing, the 
results on the three biological substrate the maximum detachment force were relatively low 




Figure 61. Adhesion properties of prepared films: maximum detachment force (MPa) of 
trilayer films tested on bovine liver tissue (values represented as mean (n = 3) and with error 
bar representing standard deviation). 
 
 
Figure 62. Adhesion properties of prepared films: total work (mJ) of trilayer films tested on 




6.1.3 Mechanical properties 
The tensile mechanical resistance of the trilayer films studied showed that there was no 
significant difference (p>0.05) in yield strength (Fig. 63). 
 
Figure 63. Mechanical properties of prepared trilayer films: yield strength (MPa) tested on 
material testing machine (values represented as mean (n = 3) and with error bar representing 
standard deviation). 
 
Whereas, films containing HPC alone and HPC+HEC in the third layer were more elastic 
(Fig. 64) than films containing HPC+HPMC in the third layer (p<0.05). 
As for the elongation at break (Fig. 65), it was relatively low and significantly different 
(p<0.05) for films containing HPC+HEC or HPC+HPMC in the third layer. The addition of 
HEC and HPMC to third layer, and the addition of GELA to the second layer, significantly 
reduced the elongation of these films. 
In addition, puncture strength (Fig. 66) was relatively low significantly different (p<0.05) for 





Figure 64. Mechanical properties of prepared trilayer films: Young’s modulus (MPa) tested 
on material testing machine (values represented as mean (n = 3) and with error bar 
representing standard deviation). Films with HPC alone in the third layer were set as control. 
The symbol (*) denotes statistical significance from the control group (p<0.05). 
 
 
Figure 65. Mechanical properties of prepared films: elongation at break (%) tested on 
material testing machine (values represented as mean (n = 3) and with error bar representing 
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standard deviation). Films with HPC alone in the third layer were set as control. The symbol 
(*) denotes statistical significance from the control group (p<0.05). 
 
 
Figure 66. Mechanical properties of prepared trilayer films: puncture strength (N) tested on 
material testing machine (values represented as mean (n = 3) and with error bar representing 
standard deviation). Films with HPC alone in the third layer were set as control. The symbol 
(*) denotes statistical significance from the control group (p<0.05). 
 
6.1.4 Measurement of in ex vivo residence time 
The ex vivo residence time was measured using porcine mucosa and a modified compendial 
disintegration apparatus. The results obtained are presented in Table X.  
 






*values represented as mean ± S.D. (n = 3) 
 
Formulation Ex vivo residence time (min)* 
NP+HPC/ HPC / HPC   
NP+HPC/ GEL A+HPC / HEC+HPC 
NP+HPC/ GEL A+HPC / HPMC+HPC 
289 ± 9.64 
163 ± 2.65 
221 ± 3.61 
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6.1.5 Measurement of in vivo residence time 
In vivo residence time for all the formulations was determined in healthy human volunteers 
and the results are presented in Figure 67. No volunteer felt heaviness of the buccal patch at 
the place of attachment because of the moderate thickness (0.15 mm) and light weight (75 
mg) of the patch. 
 
Figure 67. In vivo residence time of the trilayer films tested in healthy volunteers (values 
represented as mean (n = 3) and with error bar representing standard deviation). 
 
6.1.6 Swelling and erosion index  
The swelling properties of the prepared films were measured in pH 6.8 phosphate buffer 
solution. The determination of the swelling properties of the prepared films was extremely 
difficult, because the gelled films were very fragile, making their recovery from the Petri dish 
and weighing impossible. A method consisting in removing the excess of liquid around the 
swollen film directly in the weighing container was then adopted. 
The films exhibited a high degree of swelling (Fig. 68), while still maintaining their structural 
integrity for a reasonable time period. The degree of swelling increased with time. The higher 
swelling values (1612±115 %) were obtained from films containing HPMC+HPC as the third 
layer. 
Erosion index (Fig. 69) was calculated by drying the swollen film in an oven. The films 
showing higher swelling index had higher erosion index, although their erosion index was 
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low in the beginning. On the whole, the erosion index was low in the case of films containing 
HPC alone as the third layer. 
 
Figure 68. Swelling behavior of the prepared trilayer films tested in pH 6.8 phosphate buffer 
(values represented as mean (n = 3) and with error bar representing standard deviation). 
 
 
Figure 69. Erosion behavior of the prepared trilayer films tested in pH 6.8 phosphate buffer 





6.1.7 In vitro drug release study 
A homemade device was used to study the in vitro drug release profile from HPMC and HEC 
based trilayer films (Fig. 70) and the theoretical weights and percentage weights of each 
individual layer in trilayer films are reported in Fig. 71. This study was performed using 5 
mL and 10 mL of simulated saliva as the dissolution medium.  
The release of CHX from HPC+NP/HPC+GELA/HPC+HPMC films in 5 mL dissolution 
medium is shown in Fig. 72. The mean percentage of drug released was 39.3±0.9 % at the 
end of the test (after 6 h, Fig. 73), corresponding to 1.780±0.040 mg of the drug (Fig. 74). 
The drug released at 6 h was slightly less than the amount released at 5 h (46.16±0.65 %). 
This behaviour could be due to the second layer swelling, generating a temporary reduction 
of drug concentration in the medium, justifiable by a specific hydrodynamic condition. In 
fact, when the volume of the dissolution medium was increased to 10 mL, the curve showed 
only a brief stop in the drug release. The 10 mL release profile (Fig. 73) showed a higher 
percentage of drug released at 6 h (48.5±3.9 %, corresponding to 2.170±0.150 mg of the 
drug) than the release profile measured in 5 mL dissolution medium, and after 24 h the drug 
released was 90.7±3.5 % (Fig. 73). The reason for higher drug release at 6 h using 10 mL of 
release medium was due to higher percent of mass loss of films (23.63±3.21 %) compared to 
5 mL release medium (18.9 ±0.79 %). 
                     
 









Figure 72. In vitro drug release and mass loss profile of the HPMC-based trilayer films tested 
in 5 mL of simulated saliva (values represented as mean (n = 3) and with error bar 
































Figure 73. In vitro drug release and mass loss profile of the HPMC-based trilayer films tested 
in 10 mL of simulated saliva (values represented as mean (n = 3) and with error bar 
representing standard deviation). 




Figure 74. Profile of the amount of drug released from the HPMC-based trilayer films tested 
in 5 and 10 mL of simulated saliva (values represented as mean (n = 3) and with error bar 




























The CHX release from HPC+NP/HPC+GELA/HPC+HEC films is shown in Figs. 75 and 76. 
The profile of drug released using 5 mL of the release medium (Fig. 75) shows 37.6±3.8 % of 
drug released after 4 h, which is equivalent to 1.67±0.16 mg of the drug (Fig. 77). Then, a 
small decrease to 28.8±7.73 %, equivalent to 1.28±0.35 mg of CHX, was observed at 5 h. 
This, like in the previous case, may be attributed due to absorption of the drug from the 
dissolution medium in the empty swelled layer, hence the movement of diffusing drug was 
temporary reversed from dissolution medium towards the film. Unlike the previous release 
profile (Fig. 73), a similar behaviour was observed also when 10 mL of release medium were 
used (Fig. 76), but the decrease in the drug release was anticipated at 4 h (19.43±7.75 %, 
equivalent to 0.88±0.36 mg of CHX) in comparison to the 3 h time point (33.63±0.84 %). 
However, after 4 h the drug release progression was restored, and after 24 h the final drug 
release resulted to be 80.0±0.6 %. It has to be considered that after 6 h the amount of the drug 
released in 10 mL dissolution medium was higher (2.32±0.09 mg) with respect to 5 mL 
dissolution medium (1.94±0.34 mg, Fig. 77). It was also observed that the release behaviour 
was related to the mass loss of the film. Actually, in the release study performed using 10 mL 
release medium, the percent mass loss was 13.0±2 % at 4 h and 21.6±2.32 % at 5 h: this 
increase in mass loss from 4 h to 5 h can be related to the restoring of the drug release profile 
(45.19±2 % drug released after 5 h). 
 
Figure 75. In vitro drug release and mass loss profile of the HEC-based trilayer films tested 

































Figure 76. In vitro drug release profile of the HEC-based trilayer films tested in 10 mL 




Figure 77. Profile of the amount of drug released from HEC-based trilayer films tested in 5 
and 10 mL simulated saliva (values represented as mean (n = 3) and with error bar 




























Figures 78 and 79 show the comparative release profiles of HPMC- and HEC-based trilayer 
films in different volumes of the dissolution medium. Relatively, the percent drug release 
from the HEC-based films was higher in 5 mL (43.7±6.9 %) at 6 h and lower in 10 mL 
(80.0±0.6 %) dissolution medium at 24 h. Whereas, HPMC-based films showed percent drug 
release of 39.3±0.9 % in 5 mL at 6 h and 90.7±3.5 % in 10 mL dissolution medium at 24 h. 
The percent mass loss of HPMC- and HEC-based films at 6 h when 5 mL of dissolution 
medium was used were 18.9±0.79 % and 14.35±1.33 %, respectively. These values suggest 
that 15.01 mg of HPMC-based films and 11.38 mg of HEC-based-films have been eroded 
respectively. Whereas, when 10 mL release medium was used, the percent mass loss of 
HPMC- and HEC-based films at 24 h were 77.29±3.33 % and 76.22±2.21 %, these values 
corresponding to the erosion of 61.3±3.23 mg and 60.75±2.21 mg respectively. At the end of 
the dissolution, i.e. after 24 h, a portion of the film, that was supposed to be the first layer, 
was still attached to the flange (as shown in Figs. 74 and 76).   
 
Figure 78. Comparison of in vitro drug release and mass loss profiles of the HPMC- and 
HEC-based trilayer films tested in 5 mL simulated saliva (values represented as mean (n = 3) 
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Figure 79. Comparison of in vitro drug release and mass loss profiles of the HPMC- and 
HEC-based trilayer films tested in 10 mL simulated saliva (values represented as mean (n = 
3) and with error bar representing standard deviation). 
 
The comparison of the amount of drug released from HPMC- and HEC-based trilayer films 
are shown in Figs. 80 and 81.The percentage amount of drug loaded in the third layer for both 
formulations was 57.14% (equivalent to 2.5 mg) with respect to the total amount of the drug 
in all the three layers (equivalent to 4.4 mg). When the in vitro release was performed using 
5mL of the dissolution medium, 1.78±0.04 mg of CHX for HPMC- and 1.94±0.34 mg of 
CHX for HEC-based films were released in 6 h (Fig. 80). Whereas, in the case of 10 mL 
release medium, 4.0±0.1 mg of CHX for HPMC- and 3.5±0.0 mg of CHX for HEC-based 
films were released in 24 h (Fig. 81). In comparison, HEC-based films showed slightly higher 
drug release with respect to HPMC-based films when 5 mL of dissolution volume were used. 
Whereas, HPMC-based films showed higher percent drug release (p>0.05) compared to 
HEC-based films when 10 mL of dissolution volume were used. Hence, the results suggest 
that the HPMC polymer in the third layer confers the film a superior drug release profile 
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Figure 80. Comparison of the amount of drug released from HPMC- and HEC-based trilayer 
films tested in 5mL of simulated saliva (values represented as mean (n = 3) and with error bar 
representing standard deviation). 
 
 
Figure 81. Comparison of the amount of drug released from HPMC- and HEC-based trilayer 
films tested in 10 mL of simulated saliva (values represented as mean (n = 3) and with error 




















































In addition, the comparison of in vitro release profiles for HPMC- and HEC-based films 
coupled with their respective mass loss profiles showed that both release profiles were better 
when 10 mL of dissolution medium were used. In both trilayer films the polymer content in 
the third layer produced a water-swollen gel-like state controlling the drug release. 
Furthermore, it was clear from the plots that the drug release was governed by the volume of 
the dissolution medium used and by swelling and erosion of the polymer present in the third 
layer. 
Finally, these findings suggest that the polymers used in the third layer adequately controlled 
the release of the drug from the films. Therefore, a rate-controlling layer in the film could be 
used to control the drug release to have a local action in the oral cavity. 
 
6.1.8 In vitro sterility test  
The sterility test was intended for detecting the presence of viable forms of bacteria in the 
preparations using agar medium. The tests were carried out under aseptic conditions to avoid 
contamination of the films during the test.  
The films tested did not show any growth of microorganisms for 14 days, which indicates 
that the adopted manufacturing conditions assured the production of sterile dosage forms and 





The rational design of the multilayer film allowed us to develop a mucoadhesive, flexible, 
film for local delivery of chlorhexidine digluconate in the oral cavity for the treatment of oral 
diseases and wound healing applications. 
Initial preformulaton studies led to selection of the best film forming polymers.  
The biopolymer-based multilayer films were successfully prepared by double casting method. 
The mucoadhesive layer containing HPC and the novel product showed good mucoadhesion 
that led to good residence time of the dosage form. Furthermore, a biological study of novel 
product successfully demonstrated its anti-inflammatory and wound healing properties.  
The supportive layer containing HPC alone or HPC+GEL A enhanced the mechanical 
properties of the multilayer films for their convenient detachment from the substrate and 
handling purposes. 
The local drug delivery layer containing HPC+HPMC and HPC+HEC enabled the controlled 
release of chlorhexidine digluconate, which could reduce the possibility of bacterial infection 
in the wound site and accelerate the wound healing process. 
The good swelling index and convenient in vitro residence of the trilayer films provided 
prolonged drug release, therefore can be selected for the development of multilayer films for 
effective therapeutic uses. 
Whereas, ex vivo studies on different biological substrates provided information on possible 
adhesion of our final formulation in oral diseases or dental complications. 
The sterility test of the films successfully confirmed that the films were sterile and might be 
used for wound healing applications. 
Finally, our studies suggest that the ease of preparation of multilayer films, their adhesion on 
the wounded site, the mechanical flexibility of films makes their application simpler, 
furthermore the release control of active molecules and their protective function pave the path 
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